| Nasdaq: ZLCS
Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. It has a portfolio of clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA.